Home › Upcoming votes › Wave Life Sciences Ltd.
Read the proxy statement on EDGARWave Life Sciences Ltd.: past votes
Ballot read from the proxy statement and checked. As listed in Wave Life Sciences Ltd.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | ELECTION OF DIRECTORS Director election |
Board | For | 9 nominees; support 85% to 99.7% |
| 2 | Ratify Appointment of Independent Registered Public Accounting Firm Auditor |
Board | For | 99.5% support |
| 3 | APPROVAL OF AN AMENDMENT TO THE AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN | Board | For | — |
| 4 | NON-BINDING ADVISORY RESOLUTION ON APPROVAL OF EXECUTIVE COMPENSATION AS DISCLOSED IN THIS PROXY STATEMENT Say on pay |
Board | For | 99.2% support |
From Wave Life Sciences Ltd.’s Form 8-K, filed August 11, 2025, for the meeting held August 5, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Paul B. Bolno, M.D., MBA | 99% | — |
| Elect Director: Mark H.N. Corrigan, M.D. | 99.1% | — |
| Elect Director: Christian Henry | 85% | — |
| Elect Director: Peter Kolchinsky, Ph.D. | 99.6% | — |
| Elect Director: Adrian Rawcliffe | 99.7% | — |
| Elect Director: Ken Takanashi | 95% | — |
| Elect Director: Aik Na Tan | 99.7% | — |
| Elect Director: Gregory L. Verdine, Ph.D. | 99.6% | — |
| Elect Director: Heidi L. Wagner, J.D. | 97% | — |
| 2. The re-appointment of KPMG LLP to serve as the Company's independent registered public accounting firm and independent Singapore auditor | 99.5% | Approved |
| 3. The Company's payment of cash and equity-based compensation to the Company's non-employee directors for their service on the Board of Dir | 99.8% | Approved |
| 4. The amendment to the Company's 2021 Equity Incentive Plan, as amended, in the manner and on the basis set forth in the Proxy Statement, w | 81% | Approved |
| 5. A general authorization for the directors of the Company to allot and issue ordinary shares of the Company, in the manner and on the basi | 78% | Approved |
| 6. On a non-binding, advisory basis only, the compensation of the Company's named executive officers, in the manner and on the basis set for | 99.2% | Approved |
The five managers that reported the most shares voted at Wave Life Sciences Ltd.’s August 5, 2025 meeting, from their Form N-PX filings. This is how they voted then; it says nothing about how they will vote this time. Every manager’s vote.
| Item | RA CAPITAL MANAGEMENT, L.P. | ADAGE CAPITAL PARTNERS GP, L.L.C. | BlackRock | T. Rowe Price | MAVERICK CAPITAL LTD |
|---|---|---|---|---|---|
| Elect Director: Paul B. Bolno, M.D., MBA | — | — | For | For | — |
| Elect Director: Mark H.N. Corrigan, M.D. | — | — | For | For | — |
| Elect Director: Christian Henry | — | — | Against | For | — |
| Elect Director: Peter Kolchinsky, Ph.D. | — | — | For | For | — |
| Elect Director: Adrian Rawcliffe | — | — | For | For | — |
| Elect Director: Ken Takanashi | — | — | For | For | — |
| Elect Director: Aik Na Tan | — | — | For | For | — |
| Elect Director: Gregory L. Verdine, Ph.D. | — | — | For | For | — |
| Elect Director: Heidi L. Wagner, J.D. | — | — | For | For | — |
| 2. The re-appointment of KPMG LLP to serve as the Company's independent registered public accounting firm and independen | — | — | For | For | — |
| 3. The Company's payment of cash and equity-based compensation to the Company's non-employee directors for their service | — | — | For | For | — |
| 4. The amendment to the Company's 2021 Equity Incentive Plan, as amended, in the manner and on the basis set forth in th | — | — | For | For | — |
| 5. A general authorization for the directors of the Company to allot and issue ordinary shares of the Company, in the ma | — | — | Mixed | For | — |
| 6. On a non-binding, advisory basis only, the compensation of the Company's named executive officers, in the manner and | For | For | For | For | For |
| TO APPROVE, ON A NON-BINDING, ADVISORY BASIS ONLY, THE FREQUENCY OF HOLDING FUTURE SHAREHOLDER ADVISORY VOTES ON THE COM | -- | -- | For | -- | -- |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.